麝香四黄汤联合重组组织型纤溶酶原激活剂治疗急性缺血性脑血管病临床研究  

Clinical Study on Shexiang Sihuang Tang Combined with Recombinant Tissue Plasminogen Activator for Acute Ischemic Cerebrovascular Disease

作　　者：刘金平 孙燕燕 LIU Jinping;SUN Yanyan

机构地区：[1]开封市祥符区中医院内科,河南开封475100

出　　处：《新中医》2021年第2期39-42,共4页New Chinese Medicine

摘　　要：目的:观察麝香四黄汤联合重组组织型纤溶酶原激活剂(rt-PA)治疗急性缺血性脑血管病(AICD)的临床疗效。方法:选取90例AICD患者,随机分为参照组及试验组各45例。参照组采用rt-PA静脉溶栓治疗,试验组在参照组基础上联合麝香四黄汤治疗。比较2组临床疗效、实验室指标及不良反应发生率。结果:试验组总有效率为93.33%,明显高于参照组的66.67%(P<0.05)。治疗后,2组血清神经元特异性烯醇化酶(NSE)、内皮素-1 (ET-1)水平均较治疗前降低(P<0.05),血清超氧化物歧化酶(SOD)、一氧化氮(NO)水平均较治疗前升高(P<0.05);试验组血清NSE、ET-1水平均低于参照组(P<0.05),血清SOD、NO水平均高于参照组(P<0.05)。试验组不良反应发生率为6.67%,参照组为4.44%,2组比较,差异无统计学意义(P>0.05)。结论:麝香四黄汤联合rt-PA治疗AICD,可有效减轻患者的神经功能受损情况,改善其血管功能,且不良反应发生率低。Objective:To observe the clinical effect of Shexiang Sihuang tang combined with recombinant tissue plasminogen activator(rt-PA) for acute ischemic cerebrovascular disease(AICD). Methods:A total of 90 cases of AICD patients were selected and randomly divided into the reference group and the experiment group,45 cases in each group. The reference group was treated with intravenous thrombolysis with rt-PA,and the experiment group was additionally treated with Shexiang Sihuang tang based on the treatment of the reference group. The clinical effect,the laboratory indexes and the incidence of adverse reactions in the two groups were compared. Results:The total effective rate was 93.33% in the experiment group, significantly higher than that of 66.67% in the reference group(P<0.05). After treatment, the levels of neuron specific enolase(NSE) and endothelin-1(ET-1) in serum in the two groups were decreased when compared with those before treatment(P<0.05),and the levels of superoxide dismutase(SOD) and nitric oxide(NO) in serum were increased(P<0.05);the levels of NSE and ET-1 in serum in the experiment group were lower than those in the reference group(P<0.05),and the levels of SOD and NO in serum were higher(P<0.05). The incidence of adverse reactions was 6.67% in the experiment group and 4.44% in the reference group,there being no significance in the difference(P>0.05). Conclusion:The therapy of Shexiang Sihuang tang combined with rt-PA for AICD can effectively relieve the neurological impairment and improve the vascular function of patients,with low incidence of adverse reactions.

关 键 词：急性缺血性脑血管病 麝香四黄汤 重组组织型纤溶酶原激活剂 神经功能 血管功能 不良反应 

分 类 号：R743.3[医药卫生—神经病学与精神病学]